Athira Pharma, Inc.(ATHA)Earnings, Financials & Key RatiosAthira Pharma, Inc. (ATHA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on external financing is underscored by a rapid erosion of cash reserves, which fell from $90.6 million in 2023Q4 to $32.8 million in 2026Q1.
Athira Pharma, Inc. (ATHA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Recent stock market news and headlines for Athira Pharma, Inc. (ATHA)
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced ATHA Energy Corp. (TSX-V: SASK; OTCQX: SASKF and FRA: X5U), a uranium mineral exploration company, has qualified to trade on the OTCQX® Best Market. ATHA Energy Corp. upgraded to OTCQX from the OTCQB® Venture Market.
White Rock, British Columbia--(Newsfile Corp. - June 16, 2026) - Athena Gold Corporation (CSE: ATHA) (OTCQB: AHNRF) ("Athena" or the "Company") is pleased to provide an exploration update from its Excelsior Springs Project ("Excelsior" or the "Project") in Nevada. Mammoth Minerals Limited (ASX: M79) ("Mammoth") has been aggressively exploring Excelsior pursuant to its option agreement to earn an 80% interest in the Project over five years, providing Athena a free-carry to Definitive Feasibility Study thereafter (see Company press releases dated June 2, 2025, and August 22, 2025).
Key metrics vs top competitors for Athira Pharma, Inc. (ATHA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.34 | $17.12M | -0.17 | — | — | -290.81% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $2.51 | $255.45M | -2.89 | -86.92% | -1971.7% | -101.76% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $2.66 | $246.51M | -4.93 | — | — | -38.76% | — | |
| $3.95 | $68.19M | -2.94 | — | -1070.26% | — | — |
Athira Pharma, Inc. (ATHA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Athira Pharma, Inc. (ATHA) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Mar 26, 2026·SEC
Mar 19, 2026·SEC
Get notified when ATHA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Athira Pharma, Inc. (ATHA) stock FAQ — growth, dividends, profitability & financials explained
Athira Pharma, Inc. (ATHA) reported a net loss of $129.4M for fiscal year 2025.
Athira Pharma, Inc. (ATHA) has a return on equity (ROE) of -290.8%. Negative ROE indicates the company is unprofitable.
Athira Pharma, Inc. (ATHA) had negative free cash flow of $52.0M in fiscal year 2025, likely due to heavy capital investments.
